Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Conferences | Events

GenNext Technologies Announces $2.5M Grant Award to Commercialize In-Cell Protein Footprinting Instrumentation

publication date: Apr 4, 2022
 | 
author/source: GenNext Technologies

gennext-technologies-announces-25m-grant-award

GenNext Technologies, Inc., a growth-stage company providing biopharmaceutical drug discovery systems and services, announce the receipt of a two year, Phase II SBIR grant for a project titled "In-Cell Automated Flash Oxidation (IC-AutoFox™) Protein Footprinting System."

The grant was awarded by the National Institute of General Medical Systems (NIGMS) of the U.S. Department of Health and Human Services. The purpose of the grant is to extend GenNext’s breakthrough Hydroxyl Radical Protein Footprinting (HRPF) technology and methods to studies involving living cells.

This award of $2.5 million brings total funding from NIGMS for the GenNext platform to $9.5 million.

The Flash Oxidation (Fox™) Protein Footprinting System is currently being used by the biopharmaceutical industry to perform Higher Order Structure (HOS) analysis of proteins with an emphasis on biologic therapeutics, the most rapidly growing segment in this area. The Fox System helps researchers develop safer and more effective biotherapeutics by revealing important information about protein interactions and
structural changes.

With the support of this NIGMS grant, GenNext can now leverage its proprietary technology and considerable knowhow to develop a fully automated platform that will study drug induced HOS structure changes within living cells, with its first system designed for in vivo protein footprinting studies. This includes drug candidate activity for G protein-coupled receptor therapeutics and ion channel blockers. Thus, in-cell protein footprinting technology will, for the first time, empower scientists to survey the complex milieu of biological responses to therapeutic candidates. By studying drug response within living cells, researchers will obtain a more accurate depiction of efficacy and potential side effects.

"With this award, we will complete our in-cell protein footprinting R&D program, culminating in a revolutionary new tool to study protein structure, protein interactions, and drug interactions in living cells. Soon, researchers will study living cells with a new level of simplicity and elegance, while generating unprecedented levels of actionable data," said Scot R. Weinberger, Founder and CEO of GenNext. "We’re truly delighted to receive our tenth NIGMS grant award as further validation of our leadership in commercializing novel and robust protein footprinting technology."

"It's very exciting to watch as the GenNext platform is being adopted by many different laboratories and emerges as an essential method in structural biology labs," notes Professor Lisa Jones from University of California San Diego and inventor of in vivo protein footprinting. "I look forward to collaborating with the GenNext team to produce the world’s first in-cell protein footprinting system. As demonstrated in our laboratory, the application of this important technique to living tissues and small organisms will enable, for the first time, HRPF studies of storage diseases."

 

About GenNext Technologies

Located in the San Francisco Bay Area, GenNext Technologies, Inc., is a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers investigating biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our powerful, compact, and cost-effective platform enables researchers to conduct reproducible Higher Order Structure experiments quickly, easily, and safely. We help our customers accelerate biopharmaceutical development, while improving therapeutic efficacy and safety. Ultimately, our mission is to enable structural biology researchers to discover and develop drug theraphies that improve human health.

 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

Today's Picks

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners